BiotechTube

ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS

Phase 2/3Active
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acquired Immune Deficiency Syndrome (AIDS)

Conditions

Acquired Immune Deficiency Syndrome (AIDS), HIV Infections

Trial Timeline

Jan 16, 2014 → Mar 1, 2027

NCT ID
NCT02016924

About ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS

ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS is a phase 2/3 stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome (AIDS). The current trial status is active. This product is registered under clinical trial identifier NCT02016924. Target conditions include Acquired Immune Deficiency Syndrome (AIDS), HIV Infections.

What happened to similar drugs?

4 of 20 similar drugs in Acquired Immune Deficiency Syndrome (AIDS) were approved

Approved (4) Terminated (4) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅Zavicefta, Ceftazidime-AvibactamPfizerApproved
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
🔄PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
🔄E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3

Hype Score Breakdown

Clinical
15
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02016924Phase 2/3Active

Competing Products

20 competing products in Acquired Immune Deficiency Syndrome (AIDS)

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
42
Ticagrelor + PlaceboAstraZenecaPhase 2
27
IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
40
Raltegravir + AtazanavirMerckPre-clinical
26
Emicizumab InjectionRochePhase 2
35
PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
40
E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3
40
COBI + DRV + NRTIsGilead SciencesPhase 3
40
StribildGilead SciencesPhase 3
40
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF PlaceboGilead SciencesPhase 2
35
Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAFGilead SciencesPhase 3
40
NNRTI + FTC/TDF + StribildGilead SciencesPhase 3
40
E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF PlaceboGilead SciencesPhase 2
35
EVG + Background regimenGilead SciencesPhase 2/3
30
EVG/COBI/FTC/TDFGilead SciencesPhase 2/3
38